Inflammatory response in mixed viral-bacterial community-acquired pneumonia

BMC Pulmonary Medicine

Antoni Torres⁶  Rosario Menendez⁵  Carlos Lapresta²  Carolina Panadero⁴  Ana L Simon⁴  María A Ruiz³  Ana B Lasierra¹  Sergio Fandos⁴  Elisa Mincholé⁴  Salvador Bello⁴ 

[1] Servicio de Bioquimica Clinica, Hospital Universitario Miguel Servet, Zaragoza, Spain;Servicio de Medicina Preventiva, Hospital Universitario Miguel Servet, Zaragoza, Spain;Servicio de Microbiologia, Hospital Universitario Miguel Servet, Zaragoza, Spain;Servicio de Neumologia, Hospital Universitario Miguel Servet, Paseo Isabel La Católica, 1-3, 50009 Zaragoza, Spain;Servicio de Neumologia, ISS/Hospital Universitario y Politécnico La Fe CIBERES, Valencia, Spain;Servicio de Neumologia, Hospital Clinic i Provincial de Barcelona – Institut d’Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Universidad de Barcelona (UB) - Ciber de Enfermedades Respiratorias (Ciberes), Barcelona, Spain

关键词: Biomarkers;    Viral pneumonia;    Community-acquired pneumonia;   

Others  :  1109572
DOI  :  10.1186/1471-2466-14-123

 received in 2013-10-04, accepted in 2014-07-23,  发布年份 2014

【 摘 要 】

Background

The role of mixed pneumonia (virus + bacteria) in community-acquired pneumonia (CAP) has been described in recent years. However, it is not known whether the systemic inflammatory profile is different compared to monomicrobial CAP. We wanted to investigate this profile of mixed viral-bacterial infection and to compare it to monomicrobial bacterial or viral CAP.

Methods

We measured baseline serum procalcitonin (PCT), C reactive protein (CRP), and white blood cell (WBC) count in 171 patients with CAP with definite etiology admitted to a tertiary hospital: 59 (34.5%) bacterial, 66 (39.%) viral and 46 (27%) mixed (viral-bacterial).

Results

Serum PCT levels were higher in mixed and bacterial CAP compared to viral CAP. CRP levels were higher in mixed CAP compared to the other groups. CRP was independently associated with mixed CAP. CRP levels below 26 mg/dL were indicative of an etiology other than mixed in 83% of cases, but the positive predictive value was 45%. PCT levels over 2.10 ng/mL had a positive predictive value for bacterial-involved CAP versus viral CAP of 78%, but the negative predictive value was 48%.

Conclusions

Mixed CAP has a different inflammatory pattern compared to bacterial or viral CAP. High CRP levels may be useful for clinicians to suspect mixed CAP.

【 授权许可】

   
2014 Bello et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Templeton KE, Scheltinga SA, van den Eeden WC, Graffelman AW, van den Broek PJ, Eric CJ, Claas ECJ: Improved diagnosis of the etiology of community-acquired pneumonia with real-time polymerase chain reaction. Clin Infect Dis 2005, 41:345-351.
• [2]Jennings LC, Anderson TP, Beynon KA, Chua A, Laing RTR, Werno AM, Young SA, Chambers ST, Murdoch DR: Incidence and characteristics of viral community-acquired pneumonia in adults. Thorax 2008, 63:42-48.
• [3]Johansson N, Kalin M, Tiveljung-Lindell A, Giske CG, Hedlund J: Etiology of community-acquired pneumonia: increased microbiological yield with New diagnostic methods. Clin Infect Dis 2010, 50:202-209.
• [4]Lieberman D, Shimoni A, Shemer-Avni Y, Keren-Naos A, Shtainberg R, Lieberman D: Respiratory viruses in adults with community-acquired pneumonia. Chest 2010, 138:811-816.
• [5]Marcos MA, Camps M, Pumarola T, Martinez JA, Martinez E, Mensa J, Garcia E, Peñarroja G, Dambrava P, Casas I, de Jiménez Anta MT, Torres A: The role of viruses in the aetiology of community-acquired pneumonia in adults. Antivir Ther 2006, 11:351-359.
• [6]Johnstone J, Majumdar SR, Fox JD, Marrie TJ: Viral infection in adults hospitalized with community-acquired pneumonia. Chest 2008, 134:1141-1148.
• [7]Cillóniz C, Ewig S, Polverino E, Marcos MA, Esquinas C, Gabarrús A, Mensa J, Torres A: Microbial aetiology of community-acquired pneumonia and its relation to severity. Thorax 2011, 66:340-346.
• [8]Niederman MS: Viral community-acquired pneumonia. If we do not diagnose it and do not treat it, can it still hurt us? Chest 2010, 138:767-769.
• [9]Treanor J: Viral pneumonia. In Fishman’s pulmonary diseases. Fourth edition. Edited by Fishman AP, Elias JA, Fishman JA, Grippi MA, Senior MR, Pack AI. New York: McGraw Hill Medical; 2008:2373-2396.
• [10]Krüger S, Ewig S, Papassotiriou J, Kunde J, Marre R, von Baum H, Suttor N, Welte T, the CAPNETZ study group: Inflammatory parameters predict etiologic patterns but do not allow for individual prediction of etiology in patients with CAP – Results from the German competence network CAPNETZ. Resp Res 2009, 10:65.
• [11]Menendez R, Sahuquillo-Arce JM, Reyes S, Martinez R, Polverino E, Cilloniz C, Cordoba JG, Montull B, Torres A: Cytokine activation patterns and biomarkers are influenced by microorganisms in community-acquired pneumonia. Chest 2012, 141:1537-1545.
• [12]Ruuskanen O, Lahti E, Jennings LC, Murdoch DR: Viral pneumonia. Lancet 2011, 377:1264-1275.
• [13]Flood R, Badik J, Aronoff S: The utility of serum C-reactive protein in differentiating bacterial from nonbacterial pneumonia in children. Pediatr Infect Dis J 2008, 27:95-99.
• [14]Niederman MS: Biological markers to determine eligibility in trials for community-acquired pneumonia: a focus on procalcitonin. Clin Infect Dis 2008, 47:S127-S132.
• [15]Gilbert DN: Procalcitonin as a biomarker in respiratory tract infection. Clin Infect Dis 2011, 52:S346-S350.
• [16]Cuquemelle E, Soulis F, Villers D, Roche-Campo F, Ara Somohano C, Fartoukh M, Kouatchet A, Mourvillier B, Dellamonica J, Picard W, Schmidt M, Boulain T, Brun-Buisson C: Can procalcitonin help identify associated bacterial infection in patients with severe influenza pneumonia? A multicentre study. Intensive Care Med 2011, 37:796-800.
• [17]Hammond NE, Corley A, Fraser JF: The utility of procalcitonin in diagnosis of H1N1 influenza in intensive care patients. Anaesth Intensive Care 2011, 39:238-241.
• [18]Ahn S, Kim WY, Kim SH, Hong S, Lim CM, Koh Y, Lim KS, Kim W: Role of procalcitonin and C-reactive protein in differentiation of mixed bacterial infection from 2009 H1N1 viral pneumonia. Influenza Other Respi Viruses 2011, 5:398-403.
• [19]Ingram PR, Inglis T, Moxon D, Speers D: Procalcitonin and C-reactive protein in severe 2009 H1N1 influenza infection. Intensive Care Med 2010, 36:528-532.
• [20]Morgenthaler NG, Struck J, Alonso C, Bergmann A: Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay. Clin Chem 2005, 51:1823-1829.
• [21]Coiras MT, Aguilar JC, Garcia ML, Casas I, Perez Breña P: Simultaneous detection of fourteen respiratory viruses in clinical specimens by two multiplex reverse transcription nested-PCR assays. J Med Virol 2004, 72:484-495.
• [22]Balada-Llasat JM, LaRue H, Kelly C, Rigali L, Pancholi P: Evaluation of commercial ResPlex II v2.0, MultiCode-PLx, and xTAG respiratory viral panels for the diagnosis of respiratory viral infections in adults. J Clin Virol 2011, 50:42-45.
• [23]Diederen BMW, van der Eerden MN, Vlaspolder F, Boersma WG, Kluytmans JA, Peeters MF: Detection of respiratory viruses and Legionella spp. by real-time polymerase chain reaction in patients with community acquired pneumonia. Scand J Infect Dis 2009, 41:45-50.
• [24]Cho SH, Hong SB, Ko GB, Lee Y, Park HJ, Park SY, Moon SM, Cho OH, Park KH, Chong YP, Kim SH, Huh JW, Sung H, Do KH, Lee SO, Kim MN, Jeong JY, Lim CM, Kim YS, Woo JH, Koh Y: Viral infection in patents with severe pneumonia requiring intensive care unit admission. Am J Resp Crit Care Med 2012, 186:325-332.
• [25]Engel MF, Paling FP, Hoepelman AI, van der Meer V, Oosterheert JJ: Evaluating the evidence for the implementation of C-reactive protein measurement in adult patients with suspected lower respiratory tract infection in primary care: a systematic review. Fam Pract 2012, 29:383-393.